Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma

Register of interests (PDF 100 KB)

Equality Impact Assessment (Guidance development) (PDF 141 KB)

Final draft guidance

Final appraisal document (PDF 268 KB)

Committee papers - ACM3 (PDF 1.73 MB)

Public committee slides - ACM3 (PDF 599 KB)

Draft guidance: 2

Appraisal consultation document (online commenting)

Appraisal consultation document (PDF version) - 2 (PDF 262 KB)

Committee papers - ACM2 (PDF 4.24 MB)

Public committee slides - ACM2 (PDF 764 KB)

Draft guidance

Appraisal consultation document (online commenting)

Appraisal consultation document (PDF version) (PDF 233 KB)

Committee papers - ACM1 (PDF 9.54 MB)

Public committee slides - ACM1 (PDF 740 KB)

Final stakeholder list (PDF 187 KB)

Final scope (PDF 212 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 186 KB)

Equality impact assessment (Scoping) (PDF 126 KB)

Draft scope post referral (PDF 214 KB)

Draft matrix post referral (PDF 185 KB)

Draft scope post referral (PDF 334 KB)

Draft matrix post referral (PDF 258 KB)